Former NxStage Patient David RUSH Celebrates One-Year Kidney Transplant Anniversary

Tuesday November 8, 2011

LAWRENCE, Mass., Nov. 8, 2011 /PRNewswire/ — NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that former NxStage® System One™ patient David RUSH, 29, is celebrating the one-year anniversary of his successful kidney transplant during a special event on November 9, 2011. RUSH received the transplant following more than two years of more frequent home hemodialysis with the System One.


RUSH decided to adopt home hemodialysis because his rigorous in-center, three-times-a-week treatment schedule not only left him feeling ill and fatigued, but also made his professional work as a hip hop artist particularly difficult.

With the System One, RUSH was able to take his dialysis on the road and do treatments on his own schedule. With this flexibility, RUSH was able to go on tour with renowned hip hop artist Pitbull, an opportunity he believes he could not easily have seized as an in-center patient. RUSH believes that more frequent treatments also helped increase his energy, enabling him to lose weight and improve his health enough to qualify for a kidney transplant. RUSH received a transplant in November 2010.

I believe more frequent treatment with the System One gave me the freedom and health to pursue my career and to qualify for my kidney transplant, said David RUSH. Though I am no longer a patient, I remain grateful for the opportunities daily home dialysis afforded me and hope to continue to raise awareness of kidney disease and this therapy option.

We’re pleased to celebrate with David and other patients for whom more frequent hemodialysis with the System One not only allows them to live longer, better, healthier lives, but also may better position them for transplant success, said Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical.

About the NxStage System One

The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients’ homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq:NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company’s website at

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including factors that are discussed in NxStage’s filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Kristen K. Sheppard, Esq.
Investor Relations

SOURCE NxStage Medical, Inc.

News Provided by Acquire Media